Possible increased risk of Epstein-Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply.

Prevymis (letermovir) - Merck (MSD)

Possible increased risk of Epstein-Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply. (PubMed, J Antimicrob Chemother) - Feb 5, 2026 - No abstract available
Journal • Epstein-Barr Virus Infections • Infectious Disease • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/41642712

Anthony D Anderson; Jose F Camargo

Feb 5, 2026